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Abstract
Background: There is no consensus on the definition of poor growth response after the first year of growth
hormone (GH) treatment. We determined the proportion of poor responders identified by different criteria in
children with GH deficiency (GHD) and born small for gestational age (SGA). The second aim was to analyze the
IGF-1 response in poor growth responders.
Methods: First-year height data of 171 SGA and 122 GHD children who remained prepubertal during the first GH
treatment year were retrieved from the BESPEED database and analyzed. Criteria for poor first-year response/
responsiveness were: change in height (ΔHt) SDS<0.3 or<0.5, height velocity (HV) SDS<0.5 or <1 based on the
population reference, HV SDS<− 1 based on the KIGS expected HV curve (HV Ranke SDS), studentized residual (SR)
<− 1 in the KIGS first-year prediction model.
Results: ΔHt SDS<0.5 gave the highest percentage poor responders (37% SGA, 26% GHD). Although % poor
responders were comparable for ΔHt SDS<0.3, HV SDS<+ 0.5, HV SDS<+ 1, SR<− 1, and HV Ranke SDS<− 1, these
criteria did not always identify the same patients as poor responders. Among the poor growth responders 24% SGA
and 14% GHD patients had an IGF-1 increase < 40%.
Conclusions: The different response criteria yield high but comparable percentages poor responders, but identify
different patients. This study does not provide evidence that one criterion is better than another. A limited IGF-1
generation is not the major reason for a poor growth response in the first year of GH treatment in SGA and GHD
children.
Trial registration: Retrospectively registered.
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Background
Growth hormone (GH) deficiency (GHD) and short stat-
ure as a consequence of a small size at birth (SGA) are
the most frequent indications for GH therapy in children
in Europe. Although in general a substantial fraction of
the height deficit is already recovered during the first
year of GH treatment in these growth disorders, a high
proportion has a poor growth response in the first year
of GH therapy [1]. This first year growth response is
paramount since it is the major determinant of the gain
during the subsequent treatment years and correlates
with the final height outcome [2–12].
Traditionally the growth response during the first year
of GH treatment is evaluated by auxological parameters,
such as the gain in height SDS (ΔHt SDS), the observed
height velocity (HV) expressed in cm/year or in SDS, or
the increase in HV (ΔHV) compared to the pre-treatment
year [13]. A number of definitions of poor first-year
growth response have been proposed in clinical trials and
consensus statements, such as a gain in height <0.3 SD or
<0.5 SD, a first-year HV <+ 0.5 SD or <+ 1.0 SD for age
and gender, or an increase in HV <3 cm/year compared to
the pretreatment year [14].
Another more recent method to evaluate the growth
promoting efficacy of GH treatment in short children is to
compare the observed to the expected growth response
defined by certain patient and treatment characteristics,
which has been defined as responsiveness, reflecting the
ability of an individual person to respond to GH [11, 12,
15]. First year height velocity response curves, determined
by age, treatment indication and sometimes gender (Bak-
ker et al. [16], Ranke et al. [13], and Straetemans et al.
[17]) have been published. A height velocity below − 1.0
SD on the growth response curve has been considered as
a poor response.
In an attempt to include even more parameters to de-
termine the responsiveness to GH, Ranke et al. have de-
rived prediction models for the first year response to
GH in various treatment indications. They include
among other factors birth weight, GH dose and parental
heights [18–20]. Responsiveness is expressed as a stu-
dentized residual [SR = (observed HV – predicted HV)/
SD of the predicted HV] and a SR <− 1 has been consid-
ered a poor response [12]. This implies that 16.5% of the
patients are poor responders. Although these multivari-
ate prediction models provide a more individualized
response target, some patients meet their very poor pre-
diction and are therefore not considered poor re-
sponders despite their poor absolute response.
Several conditions might explain a poor growth re-
sponse to GH administration. With the exception of a
poorly responsive growth plate, most conditions such as
poor compliance, a hidden chronic disease or a partial
GH insensitivity due to abnormalities in the GH-IGF-1
axis will limit a sufficient generation of IGF-1 during
GH administration. Different patterns of IGF-1 increase
during GH treatment between children with GHD, SGA
children and other disorders have been described previ-
ously [21, 22]. However, up to now, there have been no
previous reports comparing the commonly used mea-
sures of poor growth response with measures of poor re-
sponsiveness from prediction models and only limited
data are available on the IGF-1 increase during GH
treatment in relation to the growth response in short
GHD and SGA children.
We therefore compared the first year growth response
and responsiveness criteria in prepubertal children with
SGA and GHD, registered in the database of the BElgian
Society for PEdiatric Endocrinology and Diabetology
(BESPEED). We expected a lower percentage of poor re-
sponders using more individualized growth response tar-
gets, especially in the SGA group, where GH sensitivity
and treatment modalities are more variable. In addition,
we evaluated the IGF-1 response during the first year of
GH treatment in those children with a poor growth
response.
Methods
Subjects
The auxological data and first year treatment character-
istics of prepubertal children diagnosed with SGA and
non-acquired GHD, who had been treated exclusively
with recombinant human GH on a daily basis, were re-
trieved from the Belgian Registry of children treated
with GH (BELGROW), which is administrated by
BESPEED since 1985. The Registry stores coded data
and informed consent was secured prior to data entry.
Data of patients who started GH treatment between
January 2003 and May 2010 were analyzed.
Diagnosis of SGA or GHD was made by the treating
physician after peer-review by the other BESPEED mem-
bers. All GHD patients had a peak GH concentration ≤
10 μg/L in two provocation tests (glucagon and insulin
test). Priming before testing with respectively estrogen
and testosterone was done routinely in girls ≥8 years old
and boys ≥9 years old. GHD patients with and without de-
velopmental anatomical anomalies of the pituitary were
included. Patients with acquired GHD were excluded.
Severe GHD was defined as a peak GH response less than
5 μg/L in both provocation tests. Included SGA children
had a birth weight and/or birth length < − 2 SD [23] and a
height < − 2.5 SD at the age of 4 years and at onset of ther-
apy. Prepuberty was defined as having a testicular volume
less than 4 ml for boys and Tanner breast stage 1 for girls.
In the GHD group, patients born SGA were excluded.
In the SGA group, patients with severe GHD (peak GH
< 5 μg/L) were also excluded. Additional exclusion cri-
teria for all groups were: age ≥10 years for girls and
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≥12 years for boys at the end of the first year of GH
treatment, gestational age <30 weeks, any chronic dis-
ease or genetic syndrome interfering with a normal
growth potential, a known poor adherence to GH treat-
ment, concomitant treatment with steroids > 12 mg/
m2.day (hydrocortisone equivalent), additional previous
or current growth promoting therapy such as sex ste-
roids, oxandrolone or aromatase inhibitors. Only pa-
tients who remained prepubertal during the first
treatment year were considered for analysis.
Methods
Variables retrieved from the register were (a) status at
birth: gender, birth weight and length; (b) genetic back-
ground: mother’s height (Ht), father’s Ht; (c) patient vari-
ables at the start of the treatment period: chronological
age, Ht, weight (Wt), the highest peak GH concentration
in GH provocation tests; (d) first year GH treatment mo-
dality: average GH dose (μg/kg.day) during the first year
of GH treatment; (e) Ht, Wt after 1 year of GH treat-
ment. IGF-1 values (ng/mL) before the start and during
the first year GH treatment were retrieved from the
medical files.
Birth weight for gestational age was transformed into
SDS, based on the standards of Niklasson et al. [23]. The
midparental height (MPH) was calculated as follows: [fa-
ther’s Ht (cm) +mother’s Ht (cm) + 13 for boys/− 13 for
girls]/2 [24]. Height, weight, body mass index (BMI),
HV, and MPH were converted to SDS using Belgian ref-
erence data by Roelants et al. [25].
First-year gain in height (ΔHt) SDS and first-year
height velocity (HV) (cm/year), were calculated as the
increment in height between start of treatment and a
measurement made after minimum 9 months and max-
imum 15 months of GH treatment, subsequently scaled
to 12 months.
The observed first-year HV (cm/yr) was expressed as
SDS, either using the Flemish HV reference curve [25]
or using the reference curves for GH treated prepubertal
GHD and SGA children developed by Ranke et al. based
on the KIGS database [13]. The latter was calculated as
follows: the HV of the child in cm/year minus the mean
HV for age and diagnosis divided by the SD for age and
diagnosis.
Predicted first-year HV (cm/year) was calculated with
the KIGS first-year prediction models for GHD (GH
peak included) [18, 19] and SGA [20], provided that all
parameters required for the mathematical algorithm
were available. These prediction models are available on
the Prediction Models Web [26] and on the iGRO web-
site [27]. Differences between observed and predicted
HVs were expressed as studentized residuals (SR). SRs
were calculated as the observed HV minus the predicted
HV, divided by the SD of the predicted HV of the child.
SR is the index of responsiveness (IoR), thus the index
of an individual’s actual growth versus its unique pre-
dicted growth.
The criteria used to define a poor first-year growth re-
sponse were: (a) Δ Ht < 0.3 SD [28], (b) Δ Ht < 0.5 SD
[13], (c) HV < + 0.5 SD on the population HV reference
curves [25], (d) HV < + 1.0 SD on the population HV ref-
erence curves [25], (e) observed first-year HV more than 1
SD below the patient’s predicted first-year height velocity
(SR < − 1) [12], and (f) HV < − 1.0 SD for expected
first-year height velocity based on diagnosis specific refer-
ence data developed by Ranke et al. (HV Ranke SDS) [13].
The patients were divided into three response groups:
poor response to all criteria, questionable response (poor
response to at least 1 criterion), and good response to all
criteria.
The percentage increase in IGF-1 was calculated using
the IGF-1 value before the start of GH treatment and
the highest IGF-1 value during the first year of GH treat-
ment. A poor IGF-1 response during the first year of
GH treatment was defined as an increase of less than
40% after at least 3 months of GH therapy. This cutoff
value corresponds to the 10th percentile of IGF-1 in-
crease in GHD patients [29].
Statistical analysis
The variables were tested for normality with the one-sample
Kolmogorov-Smirnov test and are reported as medians (25–
75 percentile) or means (± SD). Student’s t test, one-way
ANOVA and Bonferroni correction were used to test for dif-
ferences between groups when the distribution of data was
normal. Otherwise Mann-Whitney-U and Kruskal-Wallis
tests were applied. Simple linear correlation analysis was
conducted using the Spearman formula. Statistical signifi-
cance was set at the 5% level (p < 0.05). IBM SPSS statistics
21® software was used for all statistical analyses. The patient
population was of sufficient size to detect a 50% lower per-
centage poor responders for the criterion SR <− 1 compared
to the criterion HV<+ 1.0 SD (α= 0.05 and 1-β= 0.8).
Results
Baseline characteristics
In total, 171 SGA patients and 122 GHD patients met
the inclusion and exclusion criteria. Sixty six children
were diagnosed with severe GHD (peak GH < 5 μg/L).
Baseline auxological characteristics at the start of GH
treatment are listed in Table 1. For both groups there
was a predominance of males (64–66%). Boys started
GH treatment at a significantly older age than girls (7.5
vs. 6.6 years, respectively; p = 0.01); 26 (=15%) SGA and
19 (=16%) GHD boys were older than 10 years at the
start of treatment. At baseline, there was no significant
difference in median Ht SDS between SGA and GHD
patients (SGA: − 3.06 SD, GHD: − 3.20 SD). The mean
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average GH dose during the first year of GH treatment
for patients with GHD was 26.9 μg/kg*day, which was
significantly lower than the dose for patients with SGA
(38.1 μg/kg*day; p < 0.001). Children born SGA had a
lower weight and BMI at start than children with GHD
(p < 0.001). Children with GHD had the largest differ-
ence between height SDS at start and MPH SDS.
Response and responsiveness after the first year of GH
treatment
As shown in Table 2, children with GHD had a signifi-
cantly greater increase in Ht SDS and HV than children
with SGA (p < 0.001). In the SGA group the mean ob-
served HV is close to the expected HV. In contrast,
GHD responded slightly worse than predicted (SR −
0.35 ± 1.13; p = 0.05).
Children with severe GHD (max. GH peak < 5 μg/L)
had a greater increase in Ht SDS (0.97 ± 0.65 vs 0.62 ±
0.42; p = 0.001), and a greater HV (cm/yr) (10.1 ± 2.8 vs.
8.4 ± 1.9; p < 0.001) than the group with less-severe GHD.
There was no significant difference in ΔHt SDS, nor in
HV (cm/yr) between SGA children with only a low birth
weight (n = 24) and SGA children with only a low birth
length (n = 38).
Comparison of poor response and poor responsiveness
criteria
One hundred and six (106) patients (=36%) met at least
one of the proposed criteria for poor response. Figure 1
shows the percentage of patients labeled as poor re-
sponders according to the different criteria. ΔHt < 0.5
SD gave the highest proportion of poor responders (37%
in SGA, 26% in GHD). ΔHt < 0.3 SD generated 15%
poor responders in SGA and 12% in GHD. HV < 0.5 SD
was seen in 17% of SGA and in 11% of GHD patients.
HV < 1.0 SD was observed in 25% of SGA and 19% of
GHD subjects. Eighteen percent of patients with SGA
and 20% of patients with GHD had an observed
first-year HV more than 1 SD below the predicted
first-year height velocity (SR < − 1). Fourteen percent of
patients with SGA and 12% of patients with GHD had a
HV < − 1.0 SD for expected first-year HV based on diag-
nosis specific reference data developed by Ranke et al.
(HV Ranke SDS < − 1).
Between the SGA and GHD group there were no sig-
nificant differences in percentages of poor responders.
In the SGA group, the percentage of poor responders
for the ΔHt < 0.5 SD criterion was significantly different
from those for the ΔHt < 0.3 SD, HV < + 0.5 SD, SR < − 1
and HV Ranke <− 1 SD criteria (p < 0.01). In the GHD
group, the percentage of poor responders for the ΔHt <
0.5 SD criterion was significantly different from those
for the ΔHt < 0.3 SD, HV < + 0.5 SD and HV Ranke <− 1
SD criteria (p < 0.05).
Although the percentages of poor responders were
comparable for the criteria ΔHt < 0.3 SD, HV < + 0.5 SD,
HV < + 1 SD, SR < − 1, and HV Ranke <− 1 SD in the
SGA and GHD group, these specific criteria did not al-
ways identify the same patients as poor responders, as
shown in Fig. 2. For example, for the criteria ΔHt < 0.3
SD, HV < + 1 SD and SR < − 1, only 17/45 SGA patients
and 7/30 GHD patients were identified as poor re-
sponders by all three criteria. For the criteria HV < + 1
SD and SR < − 1, respectively 22/45 and 11/30 patients
in the SGA and GHD group were identified by both cri-
teria as poor responders.
Poor response to all criteria was observed in 16 (10%)
SGA and 7 (7%) GHD patients, questionable response
(poor response to at least one criterion) in 49 (30%)
SGA and 34 (32%) GHD patients, and good response to
all criteria in 96 (60%) SGA and 64 (61%) GHD patients.
In the SGA group, age was significantly older in the
group with questionable response compared to the
group with good response (data not shown). There were
no other significant differences between the responder
groups in the SGA group. In the GHD group, father
height SDS was significantly lower and Δ BMI SDS was
significantly higher in the group with questionable re-
sponse compared to the group with good response.
There were no other significant differences between the
responder groups. IGF-1 could not be compared because
this parameter was available in only a minority of the pa-
tients (data not shown).
IGF-1 response of poor growth responders
Out of the 106 patients who showed a poor growth re-
sponse for at least one criterion, 70 patients had results
of at least two IGF-1 determinations available. There
were no significant differences in the growth responses
between poor responders with and without available
IGF-1 values. For SGA (n = 41) and GHD (n = 29) pa-
tients with a poor first year growth response, the mean
increase in IGF-1 was 126% (±126) and 176% (±193),
respectively.
Ten (24%) SGA and 4 (14%) GHD patients had less than
40% increase in IGF-1 during the first year of GH treat-
ment. GHD patients with blunted IGF-1 increase had a
significantly lower BMI SDS at start compared to those
with a normal increase (− 1.35 SD vs − 0.21 SD; p < 0.01)
and had mothers with a taller height (0.66 SD vs − 1.02
SD; p < 0.01), while no differences in the available auxolo-
gical parameters were found between SGA children with a
poor and a normal IGF-1 increase.
Discussion
Depending on the criteria used, between 11 and 26% of
short prepubertal GHD children, treated with a mean
GH dose of 27 mcg/kg*d and between 14 and 37% of
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short prepubertal SGA children, treated with a mean
GH dose of 38 mcg/kg*d, were found to be poor re-
sponders. ΔHt > 0.5 SD was the most stringent criterion:
26% of GHD and 37% of SGA patients treated in
Belgium did not meet this response criterion, whereas
the HV Ranke SDS < − 1 gave the lowest percentages (12
and 14%).
Our prevalence results are comparable to the findings
of Bang et al. [1] who also assessed the criteria for poor
growth response in a group of 173 GHD and 54 SGA
short prepubertal children from the Nordic countries.
Beside the inclusion of SGA born children within the
GHD group, the in- and exclusion criteria of this Nordic
study are comparable to the data in our Belgian registry
study, explaining to a great extend the similar propor-
tion of poor responders.
Bang et al. [30] have argued that the response to GH
should be clinically meaningful, implicating that treatment
should diminish rapidly the height difference with peers,
implicating a gain in height SDS of at least 0.5 SD during
the first year. This criterion is based on the observation
that the year to year change in height SDS in normal
growing children can go up to 0.3 SD [31]. So to attribute
the growth response to GH, the change in height SDS
should be at least higher than 0.3 SD. However, since the
gain in height SDS is age and diagnosis dependent [1, 16],
a fixed cutoff will favor a better response in younger chil-
dren and in severe GHD.
Fig. 1 Percentage of poor growth responders after first-year GH treatment in prepubertal children according to various criteria in SGA and GHD
patients. SGA = small for gestational age; GHD = growth hormone deficiency; SDS = standard deviation score; ΔHt = first-year gain in height; HV =
height velocity; SR = studentized residual. * HV < − 1 SD for expected first-year treatment response based on reference data developed by Ranke
et al. # p < 0,01 vs. ΔHt SDS < 0.3, HV SDS < 0.5, SR < − 1, HV Ranke SDS < − 1; @ p < 0,05 vs. ΔHt SDS < 0.3, HV SDS < 0.5, HV Ranke SDS < − 1
Fig. 2 Number of poor responders for SGA patients (bold) and GHD patients (italic). SGA = small for gestational age; GHD = growth hormone
deficiency; SDS = standard deviation score; ΔHt = first-year gain in height; HV = height velocity; SR = studentized residual. * HV < − 1 SD for
expected first-year treatment response based on reference data developed by Ranke et al.
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Comparing the annualized HV during the first year on
GH with the HV of the pre-treatment year (ΔHV, cm/
year) might give an approximation of the GH induced
HV, except in case a severely HV declining in the pre-
treatment year is present, as often seen in severe GHD.
Theoretically, ΔHV (cm/year) may be the best response
parameter to evaluate, however reliable pretreatment
height measurements are often unavailable, as was the
case in our database.
HV (cm/year) during the first year on GH treatment is
highly age dependent [1, 16]. To express HV independ-
ent of age and in relation to normal gender related refer-
ence values, an SDS for age can be calculated. However,
references are usually based on longitudinal studies with
relatively small sample sizes or on cross-sectional data.
The ability of an individual patient to respond to GH
(the responsiveness) should always be determined in
order to evaluate the growth response correctly. For ex-
ample, a patient with a first-year ΔHt of 0.7 SD would
be considered a good responder, but with a SR of, for ex-
ample, − 1.2 this patient proves to have an inadequate
response. A weakness of prediction models may be the
lack of available patient characteristics needed to calcu-
late responsiveness.
We hypothesized that a more individualized respon-
siveness criterion would yield 50% less poor responders
than the more general response criteria. This hypothesis
must be rejected because ΔHt < 0.3 SD, HV < + 0.5 SD,
HV < + 1 SD, SR < − 1 and HV Ranke SDS < − 1 SD gave
the same proportion of poor responders in both treat-
ment indications, although the GH doses are signifi-
cantly different in both diagnostic groups. This supports
the notion that there exists a continuum and overlap be-
tween partial GHD and SGA children without a postna-
tal catch up growth [32].
Although most criteria resulted in the same proportion
of poor responders they did not identify the same patients.
For example, HV < + 1 SD, the reimbursement response
criterion of the European Medicines Agency (EMA) for
GH treatment in short SGA children, generated a compar-
able amount of poor responders as the criterion SR < − 1
(respectively 25 and 18%). However, only 17 out of 45 of
these poor responders fulfilled both criteria. Hence, these
parameters cannot be used interchangeably. The fact that
there is no concordance between the groups defined by
the different criteria is interesting, but not surprising,
since the response variables are principally different from
the responsiveness parameters .
The long-term evaluation of response to GH has been
validated for the KIGS prediction models by showing that
SR is the second most important predictor of adult height
after GH treatment. All the other proposed criteria for a
poor first-year response have not been evaluated for their
ability to predict a poor adult height outcome.
In our study, respectively 24 and 14% of the poor re-
sponders in the SGA and GHD group were found to
have an insufficient IGF-1 increase in the first year. GH
insensitivity is hence not a major reason for poor growth
response in these children. GHD patients with low
IGF-1 increase had a significantly lower BMI SDS at
start compared to those with a normal increase. Nutri-
tional constraints are possibly an important cause for
the poor IGF-1 response. These children do not have
sufficient calories to be able to grow, which may explain
the poor growth response. Poor compliance is another
possible reason for the poor IGF-1 response and growth
response. Because IGF-I rises within days after GH ad-
ministration, a normal IGF-I measurement cannot rule
out poor adherence up to a week before the blood
collection.
A weakness of this study is the limited amount of
available IGF-1 values. However, no significant differ-
ences in the growth responses between poor responders
with and without available IGF-1 values were observed.
IGF-1 levels after GH might fluctuate with the duration
of GH therapy [1]. We therefore have chosen to take the
maximum level into account and not a level at fixed dur-
ation. To circumvent the problem of non-centralized deter-
mination of IGF-1, the percentage increase was calculated
on IGF-I levels determined in the same laboratory.
Conclusions
In conclusion, with the exception of the ΔHt < 0.5 SD cut-
off, the tested criteria resulted in the same proportion of
poor growth responders in GH treated SGA and GHD pa-
tients, but did not always identify the same patients as
poor responders. This study does not provide evidence
that one criterion is better than another. A critical evalu-
ation of these response parameters and their cutoff values
with respect to their capacity to detect a poor final adult
height outcome is needed to define the best poor response
parameter. A limited capacity in IGF-1 generation did not
appear to be a major reason for a poor growth response in
both GHD as SGA children.
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